

**Maternal plasma L-carnitine reduction during pregnancy is mainly attributed to  
OCTN2 mediated placental uptake and does not result in maternal hepatic fatty  
acid  $\beta$ -oxidation decline**

Mengru Bai, Qingquan Zeng, Yingchun Chen, Mingyang Chen, Ping Li, Zhiyuan Ma,  
Dongli Sun, Hui Zhou, Caihong Zheng, Su Zeng, and Huidi Jiang

Laboratory of Pharmaceutical Analysis and Drug Metabolism, College of  
Pharmaceutical Sciences, Zhejiang University, Hangzhou, China (M.B., Y.C., M.C.,  
P.L., Z.M., H.Z., S.Z., H.J.)

Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China (Q.Z.,  
D.S., C.Z.)

**Running title:** The mechanism of maternal plasma L-carnitine reduction

**Corresponding author:** Huidi Jiang

**Address:** College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China

**Tel (Fax):** +86-571-88208408

**E-mail:** [hdjiang@zju.edu.cn](mailto:hdjiang@zju.edu.cn)

The number of text pages: 36

The number of tables: 0

The number of figures: 7

The number of supplemental tables: 1

The number of supplemental figures: 2

The number of references: 51

The number of words in the *Abstract*: 238

The number of words in the *Introduction*: 747

The number of words in the *Discussion*: 1356

**Abbreviations:** Acs11, long-chain acyl-CoA synthetase 1; ATB<sup>0, +</sup>, amino acid transporter B<sup>0, +</sup>; Bdh1, 3-hydroxybutyrate dehydrogenase 1; CoA, coenzyme A; CORT, corticosterone; Cpt1a, carnitine palmitoyltransferase 1a; CT1, carnitine transporter 1; DMEM, Dulbecco's Modified Eagle's Medium; E2, estradiol; FBS, fetal bovine serum; GD, gestation day; Hmgcl, hydroxymethyl glutaryl-CoA lyase; Hmgcs2, hydroxymethyl glutaryl-CoA synthase; L-Car, L-carnitine; d<sub>3</sub>-L-Car, d<sub>3</sub>-L-carnitine; MDCK, Madin–Darby canine kidney; LD, lactation day; OCTN2,

carnitine/organic cation transporter 2; P4, progesterone; PPAR $\alpha$ , peroxisome proliferator-activated receptor  $\alpha$ ; qRT-PCR, quantitative real-time polymerase chain reaction; SDS, sodium dodecyl sulfate; TG, triglyceride; TC, total cholesterol.

## ABSTRACT

L-Carnitine (L-Car) plays a crucial role in fatty acid  $\beta$ -oxidation. However, the plasma L-Car concentration in women markedly declines during pregnancy, the underlying mechanism and the consequent on maternal hepatic  $\beta$ -oxidation has not been clarified yet. Our results showed that the plasma L-Car level in mice at gestation day (GD) 18 was significantly lower than that in non-pregnant mice, and the mean fetal-to-maternal plasma L-Car ratio in GD 18 mice was 3.0. Carnitine/organic cation transporter 2 (OCTN2) was highly expressed in mouse and human placenta and up-regulated as gestation proceeds in human placenta, while carnitine transporter (CT) 1, CT2 and amino acid transporter B<sup>0,+</sup> (ATB<sup>0,+</sup>) were extremely low. Further study revealed that renal peroxisome proliferator-activated receptor  $\alpha$  (PPAR $\alpha$ ) and OCTN2 were down-regulated, renal L-Car level was reduced while the urinary excretion of L-Car was lower in late pregnant mice than that in non-pregnant mice. Meanwhile, progesterone (pregnancy-related hormone) down-regulated the expression of renal OCTN2 *via* PPAR $\alpha$ -mediated pathway, and inhibited the activity of OCTN2, but estradiol, corticosterone and cortisol did not. Unexpectedly, the maternal hepatic level of L-Car,  $\beta$ -hydroxybutyrate (an indicator of mitochondrial  $\beta$ -oxidation) and mRNA level of several enzymes involved in fatty acid  $\beta$ -oxidation in GD 18 mice were higher than that in non-pregnant mice. In conclusion, OCTN2 mediated L-Car transfer across placenta played a major role in maternal plasma L-Car reduction during pregnancy, which did not subsequently result in maternal hepatic fatty acid  $\beta$ -oxidation decrease.

## Introduction

L-Carnitine (L-Car) is a hydrophilic quaternary amine that plays a crucial role in fatty acid  $\beta$ -oxidation. L-Car and long-chain acyl coenzyme A (CoA) form acylcarnitines by the action of carnitine palmitoyltransferase 1. Acylcarnitines are then translocated across the mitochondrial membrane by the carnitine/acylcarnitine translocase. Once inside mitochondria, carnitine palmitoyltransferase 2 removes L-Car from acylcarnitines and re-generates acyl-CoAs. L-Car then returns to the cytoplasm for another cycle while the acyl-CoAs enter  $\beta$ -oxidation (Ramsay et al., 2001; Foster, 2004). L-Car deficiency may cause fatty acid oxidation disorder, and lead to cardiomyopathy, muscle weakness, hypoglycemia and fatty liver (Frigeni et al., 2017). The plasma concentration of L-Car in pregnant women is reported to be much lower than that in non-pregnant women and keeps decline as gestation proceeds (Winter et al., 1995; Lindsay et al., 2015). At the time of delivery, the maternal plasma L-Car concentration is only half of that in non-pregnant women, which will be returned to its original level 8 weeks after delivery (Cederblad et al., 1986; Cho and Cha, 2005). It seems that pregnancy leads to a reversible secondary deficiency of L-Car (Marzo et al., 1994). However, the reasons have not been clarified yet.

In humans, L-Car homeostasis is maintained by dietary absorption, endogenous synthesis, and efficient renal reabsorption (Vaz and Wanders, 2002). About 75% of L-Car requirement is diet provided, while 25% is synthesized endogenously in the liver and kidney of adults. L-Car is eliminated in its original form by glomerular filtration in human, however, most of the filtered L-Car will be reabsorbed in kidney

by carnitine transporters, especially by carnitine/organic cation transporter 2 (OCTN2, SLC22A5), a high affinity L-Car transporter located in the apical side of renal tubular epithelial cells (Longo et al., 2016). A defect in the OCTN2 will cause urinary L-Car wasting and subsequently result in primary L-Car deficiency (Lahjouji et al., 2002). Besides OCTN2, carnitine transporter 1 (CT1, SLC22A15), CT2 (SLC22A16), and amino acid transporter B<sup>0,+</sup> (ATB<sup>0,+</sup>, SLC6A14) can also mediate L-Car uptake (Sekine et al., 1998; Nakanishi et al., 2001; Enomoto et al., 2002). Therefore, carnitine transporters in the kidney are very important for the L-Car homeostasis.

A series of physiologic changes, including increased maternal fat, blood volume, cardiac output, and blood flow to the kidneys, occur in pregnant women (Costantine, 2014). In addition, the plasma concentrations of several hormones are gradually increased during pregnancy. The plasma levels of estradiol (E2) and progesterone (P4) in pregnant women during the third trimester will reach tens to hundreds folds of the original levels (La Marca et al., 2005; Zhang et al., 2015). And the plasma concentrations of glucocorticoids (cortisol in humans and corticosterone (CORT) in rodents) are also gradually increased during pregnancy (Soldin et al., 2005; Jung et al., 2011).

It is noteworthy that the placenta mediates maternofetal transport of a variety of nutrients, including L-Car. L-Car is pivotal for the fetal organism, but fetus has limited capacity for L-Car biosynthesis (Hahn, 1981; Shenai and Borum, 1984), thus, fetus obtains almost all of the required L-Car from the maternal circulation. And the L-Car level in umbilical cord plasma is reported to be higher than that in the mother

(Talian et al., 2007; Keller et al., 2009). We hypothesized that it might be one of the reasons for the reduction of maternal plasma L-Car concentration during pregnancy. It has been reported that OCTN2 which located in the apical membrane of syncytiotrophoblasts of human placenta mediates the placental transport of L-Car (Lahjouji et al., 2004; Grube et al., 2005), however, it is not clear whether other carnitine transporters are involved in the process.

It was known that plasma lipid levels, including triglyceride (TG) and total cholesterol (TC), were markedly higher in pregnant women than that in non-pregnant women, and were increased as gestation proceeds (Alemu et al., 2018; Wang et al., 2018). In comparison with healthy controls, the levels of TG and TC were much higher in women with preeclampsia, gestational diabetes mellitus and intrahepatic cholestasis of pregnancy (Pecks et al., 2016; Layton et al., 2019). However, the mechanism also remains unknown.

Based on the above information, we hypothesized that L-Car deficiency during pregnancy might induce hepatic fatty acid oxidation disorder, and subsequently lead to the increase of plasma lipid levels. Therefore, one aim of the present study was to elucidate a possible mechanism for the reduction of maternal plasma L-Car concentration during gestation, the other aim was to explore whether such low L-Car concentration associated with plasma lipid levels rise in pregnancy.

## **Materials and methods**

### **Materials**

Fetal bovine serum (FBS), trypsin, Dulbecco's Modified Eagle's Medium (DMEM) and DMEM/F12 were purchased from GIBCO Invitrogen Life Technologies (Grand Island, NY, USA). L-carnitine (L-Car) was purchased from Meilun Biological Co. Ltd. (Dalian, China). L-carnitine (methyl-d<sub>3</sub>) (d<sub>3</sub>-L-Car) was obtained from Cambridge Isotope Laboratories, Inc. (Andover, MA, USA). E2, P4, cortisol and WY14643 were purchased from Aladdin biochemical technology co., LTD (Shanghai, China). Corticosterone (CORT) was obtained from TCI (Shanghai) Development Co., Ltd. OCTN2 antibody (species reactivity: human, mouse, rat) was obtained from Sigma-Aldrich (St. Louis, MO, USA. (SAB4300885)). GAPDH antibody and the secondary anti-rabbit and anti-mouse antibodies were obtained from Multi Sciences Biotech Corporation (Hangzhou, China). Acetonitrile was obtained from Tedia (Fairfield, OH, USA). Ammonium acetate and formic acid were obtained from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals or solvents were of the highest grade commercially available.

### **Animal experiments**

All animal procedures were performed in accordance with the 'Principles of laboratory animal care' (<http://grants1.nih.gov/grants/olaw/references/phspol.htm>) and were approved by the Institutional Animal Care and Use Committee of Zhejiang University (2015-0026). All experimental procedures were conducted as humanely as possible.



Specific pathogen free female non-pregnant and pregnant (gestational day 14, GD 14) ICR mice, age of 8 – 10 weeks, were obtained from Beijing Vital River Laboratory Animal Technology Company (Beijing, China) [SCXK (Jing) 2016-0011]. The animals were housed in cages at controlled temperature ( $22.0 \pm 1^\circ\text{C}$ ) and humidity ( $50 \pm 10$ ) % with a 12-h light-dark cycle and free access to food and water throughout the study. Mice consumed ad libitum a commercial standard mouse diet (Laboratory Rodent Diet 5001; LabDiet). No dietary manipulations were otherwise conducted and all dietary conditions were the same for the control and treated groups.

Blood, livers, kidneys, hearts and muscles of the non-pregnant ( $n = 10$ ) and pregnant (GD 18,  $n = 10$ ) mice were collected after cervical dislocation, and the fetal blood samples were collected immediately after fetuses were sacrificed by decapitation. The plasma/serum was collected immediately after centrifugation at 8000 g for 10 min and stored at  $-40^\circ\text{C}$  until analysis. Placentas of the pregnant mice at GD 15 ( $n = 8$ ) and 18 ( $n = 8$ ) were collected and the tissues were frozen in liquid nitrogen immediately after dissection and stored at  $-80^\circ\text{C}$  until analysis.

Another non-pregnant mice ( $n = 10$ , 2 mice per cage) and pregnant mice ( $n = 5$ , 1 mouse per cage) were used in the urine excretion study. On GD 16 – 18 and lactation day (LD) 8 – 10, urine samples within 24 h from pregnant or postpartum mice were collected. On another successive 3 days (day1 – day3), urine samples within 24 h from non-pregnant mice were collected.

The concentrations of L-Car in plasma, tissues and urine were determined by the LC-MS/MS method described previously (Wang et al., 2019). The mRNA and protein

levels of related genes in the liver, kidney and placenta were measured by quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. The concentrations of  $\beta$ -hydroxybutyrate in serum and liver were determined using a  $\beta$ -Hydroxybutyrate Test Kit (Colorimetric Method) (Ningbo Ruiyuan Biotechnology co., LTD, Ningbo, China).

### **Cell culture**

Parental Madin–Darby canine kidney (MDCK) cells were obtained from Peking Union Medical College (Beijing, China). MDCK-hOCTN2 cells (MDCK cells stably transfected with plasmid pcDNA3.1 (+) vector containing human OCTN2 cDNA) were constructed in our laboratory (Li et al., 2017). Cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin at 37 °C with 5% (v/v) CO<sub>2</sub>. HK-2 cells were obtained from Stem Cell Bank and maintained in DMEM/F12 medium with 10% FBS and 1% penicillin/streptomycin in a humidified 5% (v/v) CO<sub>2</sub> air atmosphere at 37 °C.

### **Cellular accumulation experiment**

MDCK-hOCTN2 cells were seeded into 24-well plates at a density of  $2 \times 10^5$ /well. On day three after seeding, cellular accumulation experiments were performed with the method described by our laboratory (Bai et al., 2017; Ma et al., 2017). Cells were washed twice and pre-incubated with Krebs-Ringer-Henseleit buffer (KRH) for 10 min at 37°C, then 200  $\mu$ L KRH containing d<sub>3</sub>-L-Car with or without pregnancy-related hormones (E2, P4, CORT and cortisol) was added to initiate accumulation for 3 min. Accumulation was terminated by removing the incubation

buffer and immediately adding ice-cold buffer. Finally, cells were washed three times with ice-cold buffer and lysed with 100  $\mu$ L 0.1% sodium dodecyl sulfate (SDS). The accumulation assay in HK-2 cells was similar to that in MDCK-hOCTN2 cells. The concentration of d<sub>3</sub>-L-Car was measured using LC-MS/MS with the method described previously (Wang et al., 2019).

### **Treatment of HK-2 cells with hormones**

HK-2 cells were seeded at a density of  $4 \times 10^5$ /well in 12-well plates. After overnight, cells were treated with or without designated concentrations of E2, P4, CORT or cortisol for 24h (refreshing the medium per 12 h), then the concentration of L-Car or mRNA expression of OCTN2 were measured. To investigate the role of peroxisome proliferator-activated receptor  $\alpha$  (PPAR $\alpha$ ) in OCTN2 expression, the cells were incubated with 100  $\mu$ M WY14643 (a PPAR $\alpha$  agonist) under 20 $\mu$ M P4 treatment.

### **Clinical Tissue Collection**

All the human placentas were obtained from uncomplicated pregnancies in accordance with ethical standards at Women's Hospital, School of Medicine, Zhejiang University. All the participants provided written informed consent. Term placentas (n = 23) were collected following natural delivery at term (38 – 40 week of gestation) and the first trimester placentas (n = 32) were acquired from interruption of the pregnancy between 8 and 10 week of gestation. For qRT-PCR and western blot, the placental samples were frozen in liquid nitrogen immediately after delivery or surgery and stored at  $-80$  °C until analysis. For immunohistochemistry, placental tissue sections were obtained by dissecting a segment (1.5 cm square, 0.5 cm thick) from the

maternal part of the placenta and were fixed in 4% formaldehyde at 4 °C for 2 days, and paraffin sections of 2 μm were generated.

### **qRT-PCR assay**

Total RNA was extracted from tissues and cells using RNA simple Total RNA Kit (Tiangen, China). Then cDNA was synthesized according to the manufacturer's protocol using PrimeScript RT Master Mix (TaKaRa, Tokyo, Japan). The resulting cDNA was amplified by qRT-PCR with SYBR<sup>®</sup> Premix EX Taq (Takara, Tokyo, Japan). Relative mRNA levels of target genes were normalized by GAPDH, using the  $\Delta\text{Ct}$  method and described as  $2^{-\Delta\text{Ct}}$ ,  $\Delta\text{Ct} = \text{Avg. Ct (Target gene)} - \text{Avg. Ct (GAPDH)}$ . To determine the fold-change of target genes, results were calculated using the  $\Delta\Delta\text{Ct}$  method and described as  $2^{-\Delta\Delta\text{Ct}}$ ,  $\Delta\Delta\text{Ct} = (\text{Avg. Ct (Target gene)} - \text{Avg. Ct (GAPDH)})_{\text{sample}} - (\text{Avg. Ct (Target gene)} - \text{Avg. Ct (GAPDH)})_{\text{control}}$ . The specific primers were showed in Supplemental Table 1.

### **Western blot analysis**

Tissues were homogenized in RIPA lysis buffer (Beyotime, Shanghai, China), and the protein concentration was determined with a BCA Protein Assay Kit (Beyotime, Shanghai, China). Proteins were mixed with loading buffer (P0015; Beyotime, Nanjing, China) and then boiled at 100 °C for 5 min. Aliquots of denatured protein were separated by SDS-PAGE (Bio-Rad, Hercules, CA) and subsequently transferred onto PVDF membrane (Millipore Corporation, Billerica, MA, USA). The membranes were blocked and incubated with primary anti-OCTN2 antibody (1:1000) or anti-GAPDH antibody (1:5000) for 4 h at room temperature. Membranes were then

washed with TBST 3 times (5 min every time) and incubated with HRP-conjugated secondary antibodies at room temperature for 2 h. After being washed with TBST again 3 times (5 min every time), signals were visualized by chemiluminescent detection using the enhanced chemiluminescence (ECL) Western blotting detection system (LI-COR Biosciences, Lincoln, NE).

### **Immunohistochemistry**

The slides were deparaffinized in xylene and rehydrated in a series of graded alcohols. After quenching endogenous peroxidase activity with 1% H<sub>2</sub>O<sub>2</sub>, the sections were rinsed with PBS and incubated with 5% BSA for 30 min at room temperature to reduce nonspecific binding, then for 16 h at 4 °C with anti-OCTN2 antibody (1:50) diluted in 5% BSA. The section was incubated with biotinylated anti-rabbit IgG antibody for 1 h at room temperature, washed, then incubated with streptavidin peroxidase for 1 h at room temperature, and followed by interaction with the DAB (3,3-diaminobenzidine) liquid substrate system (Sigma, MO, USA) for 1 min. All sections were counterstained with hematoxylin for 3 min.

### **Data analysis**

Data are expressed as mean  $\pm$  SEM. *In vitro* experiments were conducted at least two times in triplicate. IC<sub>50</sub> values were assessed by nonlinear regression using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA). Student's *t*-test was used to compare differences between two groups, while one-way ANOVA with the Dunnett's test was applied for data with more than two groups. *P* values < 0.05 were considered statistically significant.

## Results

### **The maternal plasma L-Car concentration decreased in pregnant mice**

In non-pregnant mice, plasma L-Car concentration was about 19.5  $\mu\text{M}$ , however, it was sharply reduced to 12.6  $\mu\text{M}$  in pregnant mice at gestation day (GD) 18 ( $P < 0.01$ , Fig. 1).

### **Reduction of maternal plasma L-Car level might be attributed to high placental transfer via OCTN2**

To clarify the reason for maternal plasma L-Car reduction in pregnant mice, we measured the concentrations of L-Car in the maternal and fetal plasma. As shown in Fig. 2A, the mean concentrations of L-Car were 12.6  $\mu\text{M}$  in maternal plasma and 37.8  $\mu\text{M}$  in fetal plasma, respectively. The mean fetal-to-maternal plasma concentration ratio of L-Car in GD 18 mice was 3.0. Since placental transfer of L-Car is mainly mediated by carnitine transporters, we detected the mRNA levels of Ct1, Ct2, Octn2 and Atb<sup>0,+</sup> in the placenta of pregnant mice at GD 15 and GD 18 (Fig. 2B). Our results revealed that Octn2 was highly expressed in mouse placenta, but no difference was found between GD 15 and GD 18 mice. The mRNA level of Ct1 and Atb<sup>0,+</sup> were extremely low in mouse placenta, while Ct2 was undetectable. The above data implies that OCTN2 plays a key role in placental transfer of L-Car.

We further detected the mRNA expression of carnitine transporters in human placenta. As shown in Fig. 2C, OCTN2 was highly expressed, while CT1 and CT2 were very low and ATB<sup>0,+</sup> was undetected. The mRNA and protein expression of OCTN2 in the term placenta were obviously higher than that in the first trimester

placenta (Fig. 2D). The immunohistochemical results showed that OCTN2 was expressed on the maternal side of syncytiotrophoblasts of the human term placenta (Fig. 2E). Therefore, OCTN2 also plays a crucial role in L-Car transfer across human placenta.

### **Reduction of maternal plasma L-Car level might not be attributed to renal excretion increase**

L-Car is excreted into urine by glomerular filtration, however, most of the filtered L-Car is reabsorbed in proximal tubules *via* transporters. Thus, a decrease in renal reabsorption of L-Car will also lead to plasma L-Car reduction. However, the urinary excretion of L-Car in pregnant mice during the third trimester (GD 16 – GD 18) was tremendously lower than that in non-pregnant mice (day 1 – day 3), while the excretion largely increased after delivery (LD 8 – LD 10) (Fig. 3A). The results indicate that the decreased concentration of L-Car in maternal plasma of pregnant mice in the third trimester is not attributed to urinary excretion increase.

The concentration of L-Car in the kidney of GD 18 mice (326 nmol/g) was significantly lower than that in non-pregnant mice (551 nmol/g) ( $P < 0.001$ , Fig. 3B). Moreover, the mRNA level of *Octn2* in the kidney of GD 18 mice was approximately 72% of that in non-pregnant mice ( $P < 0.001$ ), whereas the mRNA expressions of other carnitine transporters including *Ct1*, *Ct2* and *Atb*<sup>0,+</sup> were very low in the kidney (Fig. 3C). The results suggest that renal reabsorption of L-Car is decreased in late pregnancy due to down-regulated OCTN2 in the kidney.

### **OCTN2 expression was down-regulated by P4 in HK-2 cells**

To investigate the reason why renal Octn2 was down-regulated in GD 18 mice, we further explored whether pregnancy-related hormones including E2, P4, CORT and cortisol had effect on OCTN2 expression in HK-2 (a normal human proximal tubule epithelial cell line) cells. P4 (5 – 20  $\mu$ M) concentration-dependently down-regulated the mRNA level of OCTN2, while E2 did not show any effect (Fig. 4, A and B). However, 10  $\mu$ M CORT and cortisol up-regulated the mRNA level of OCTN2 in HK-2 cells (Fig. 4C). In addition, P4 reduced the concentration of L-Car in HK-2 cells with the IC<sub>50</sub> value of 10.7  $\mu$ M (Fig. 4D).

#### **P4-induced down-regulation of OCTN2 was probably through down-regulation of PPAR $\alpha$ but not PPAR $\gamma$**

It has been reported that PPAR $\alpha$  and PPAR $\gamma$  contributed to OCTN2 regulation (D'Argenio et al., 2010; Luo et al., 2014; Luo et al., 2016). In order to determine whether PPAR $\alpha/\gamma$  contributed to P4-induced OCTN2 down-regulation, we examined the mRNA expression of PPAR $\alpha/\gamma$  in HK-2 cells with or without P4 treatment. P4 (5 – 20  $\mu$ M) down-regulated the mRNA level of PPAR $\alpha$  in a concentration dependent manner, whereas the PPAR $\gamma$  expression was not markedly altered (Fig. 5, A and B). Furthermore, WY14643 (100  $\mu$ M), a PPAR $\alpha$  agonist, blocked 20  $\mu$ M P4-induced down-regulation of OCTN2 as well as PPAR $\alpha$  in HK-2 cells ( $P < 0.001$ , Fig. 5, C and D). Additionally, the mRNA level of Ppar $\alpha$  was also obviously lower in the kidney of GD 18 mice than that in non-pregnant mice ( $P < 0.05$ , Fig. 5E). The above results suggest that P4 down-regulates the expression of OCTN2 in HK-2 cells through PPAR $\alpha$ -mediated pathway.



#### **P4 inhibited OCTN2 mediated d<sub>3</sub>-L-Car uptake**

To determine whether pregnancy-related hormones inhibit the L-Car uptake mediated by OCTN2, the accumulation of d<sub>3</sub>-L-Car in MDCK-hOCTN2 cells were evaluated in the absence or presence of E2, P4, CORT or cortisol. Our data demonstrated that P4 reduced the accumulation of d<sub>3</sub>-L-Car in a concentration-dependent manner with the IC<sub>50</sub> value of 15.8 μM, whereas E2 did not (Fig. 6, A and B). High concentration (100 μM) of CORT and cortisol slightly inhibited the uptake of d<sub>3</sub>-L-Car in MDCK-hOCTN2 cells ( $P < 0.001$ , Fig. 6C). Similarly, P4 (10 and 50 μM) significantly reduced the uptake of d<sub>3</sub>-L-Car in HK-2 cells ( $P < 0.001$ , Fig. 6D).

#### **β-Oxidation of fatty acids in the liver of GD 18 mice was higher than that in non-pregnant mice**

Although the concentration of L-Car in maternal plasma was much lower in GD 18 mice than that in non-pregnant mice (Fig. 1), the L-Car concentration in the liver of GD 18 mice was significantly higher than that in non-pregnant mice ( $P < 0.01$ , Fig. 7A). Similarly, the hepatic level of β-hydroxybutyrate, an indicator of mitochondrial β-oxidation, was also obviously higher in GD 18 mice than that in non-pregnant mice ( $P < 0.001$ , Fig. 7B), while the serum level was not markedly altered ( $P > 0.05$ , Fig. 7C). To further elucidate the mechanism of hepatic β-hydroxybutyrate increase, the mRNA levels of key enzymes involved in fatty acid β-oxidation were measured. As shown in Fig. 7D, the long-chain acyl-CoA synthetase 1 (Acs11) and carnitine palmitoyltransferase 1a (Cpt1a) in the liver were up-regulated obviously in GD 18

mice compared to non-pregnant mice ( $P < 0.01$ ), however, the expressions of other genes were not changed ( $P > 0.05$ ). In addition, the enzymes involved in  $\beta$ -hydroxybutyrate synthesis, such as hydroxymethyl glutaryl-CoA synthase (Hmgcs2) and hydroxymethyl glutaryl-CoA lyase (Hmgcl), were significantly increased in the liver of GD 18 mice ( $P < 0.01$ ), while 3-hydroxybutyrate dehydrogenase 1 (Bdh1) decreased ( $P < 0.05$ ) (Fig. 7E). These results suggest that  $\beta$ -oxidation of fatty acids in the liver of GD 18 mice is higher than that in non-pregnant mice.

## Discussion

The present study investigated the mechanism of maternal plasma L-Car concentration reduction during pregnancy in mice, and found that OCTN2 mediated L-Car transfer across placenta played a major role in maternal plasma L-Car reduction, and the reduction of maternal plasma L-Car level did not induce decrease in hepatic L-Car concentration and fatty acid  $\beta$ -oxidation.

Our study found that the plasma concentration of L-Car in GD 18 mice was only 65% of that in non-pregnant mice (Fig. 1), which was consistent with the results in pregnant and non-pregnant women (Cederblad et al., 1986; Cho and Cha, 2005). We subsequently found that L-Car concentration in fetal plasma was 3 folds of that in maternal plasma of GD 18 mice (Fig. 2A). Although CT1, CT2, OCTN2 and ATB<sup>0,+</sup> can mediate L-Car uptake, however, our results revealed that only Octn2/OCTN2 mRNA was highly expressed in mouse and human placenta (Fig. 2, B and C), which indicated that OCTN2 might mediate most of the maternal–fetal L-Car transport. And the expression of OCTN2 in human placenta was up-regulated as gestation proceeds (Fig. 2D), which is possibly due to the increased demand of fetus for L-Car. In addition, although OCTN1 (SLC22A4) is expressed in the placenta and has high homology to OCTN2 (Tamai et al., 1997), however, several published studies showed that human/mouse/rat OCTN1 did not (Wu et al., 2000; Amat et al., 2003) or transported L-Car with a very low capacity (Yabuuchi et al., 1999; Tamai et al., 2000). Our study demonstrated that d<sub>3</sub>-L-Car was not a substrate of hOCTN1 using the MDCK-hOCTN1 cell model (Supplemental Fig. 1A). Moreover, we found that L-Car

concentration in MDCK-hOCTN1 cells was not higher than that in mock cells, while MDCK-hOCTN2 cells extremely higher (Supplemental Fig. 1B). Given the above, we considered that OCTN1 played a very limited role in L-Car placental transport. Therefore, we reasoned that OCTN2 located in the brush border membrane of placenta mediated L-Car uptake from maternal circulation, caused maternal plasma L-Car reduction. Future studies will be needed to elucidate how L-Car transports from the placenta to fetal circulation.

The increased renal excretion of L-Car can also lead to the reduction of maternal plasma L-Car. However, our following experiment revealed that the urinary excretion of L-Car in pregnant mice during the third trimester was lower than that in non-pregnant and postpartum mice (Fig. 3A). The result is in line with several previous reports (Marzo et al., 1994; Cho and Cha, 2005), in which they reported that pregnant women had higher urinary excretion of L-Car during the first trimester than that in non-pregnant or postpartum women, but the excretion was decreased markedly during the third trimester. Therefore, renal excretion of L-Car can be ruled out as possible reasons for the lower plasma L-Car concentration during late pregnancy in mice.

We found that the L-Car concentration and mRNA level of Octn2 in the kidney of GD 18 mice was significantly lower than that in non-pregnant mice (Fig. 3, B and C), which means that the renal reabsorption of L-Car in GD 18 mice was decreased. Our results demonstrated that P4 significantly inhibited the uptake of d<sub>3</sub>-L-Car in MDCK-hOCTN2 cells and HK-2 cells (Fig. 6, B and D), which is in consistent with

the previous report that P4 was a competitive inhibitor of L-Car uptake in BeWo cells (Rytting and Audus, 2008). Furthermore, we found that P4 down-regulated the expression of OCTN2 in HK-2 cells through PPAR $\alpha$ -mediated pathway (Fig. 5C). Meanwhile, the mRNA level of Ppar $\alpha$  was obviously lower in the kidney of GD 18 mice than that in non-pregnant mice (Fig. 5E). Thus, the reduction of L-Car reabsorption might be the result of P4-induced down-regulation and activity inhibition of renal OCTN2. In addition, we considered that the reduction of urinary excretion of L-Car might be due to reduced glomerular filtration of L-Car because of the decreased maternal plasma L-Car concentration in late pregnancy.

Besides renal excretion and placental transfer, L-Car homeostasis in humans is also maintained by dietary intake and endogenous synthesis. Cho and Cha (2005) reported that pregnant Korean women had lower L-Car intakes than non-pregnant women during the first trimester, but increased as gestation proceeds. L-Car biosynthesis involves a complex series of reactions in several tissues. The availability of  $\gamma$ -butyrobetaine in the liver and kidney is limiting for L-Car biosynthesis in humans (Rebouche et al., 1989). Ringseis et al. (2010) examined plasma samples of 79 pregnant women at delivery and found a positive correlation between plasma concentration of  $\gamma$ -butyrobetaine and L-Car, thus they proposed that low plasma concentration of L-Car in pregnant women might be the result of a diminished L-Car biosynthesis due to the lack of sufficient  $\gamma$ -butyrobetaine. However, Coskun and Dogan (2002) found that L-Car biosynthesis in rabbit liver increased gradually in late pregnancy due to increased  $\gamma$ -butyrobetaine hydroxylase activity. Fernandez (1989)

reported that liver L-Car levels were increased during late gestation in rats. There is no report regarding the L-Car biosynthesis alteration in kidney during pregnancy. Therefore, the status of L-Car biosynthesis in human liver and kidney during pregnancy remains to be investigated. In addition, volume dilution caused by plasma volume increase during pregnancy might also contribute to maternal plasma L-Car reduction.

Based on the above consideration, we thought the reasons for plasma L-Car concentration decrease in women during pregnancy are complicated. The reduction of plasma L-Car concentration in pregnant women during the first trimester might be due to dietary intake reduction and urinary excretion increase, and the reduction during the third trimester might be mainly attributed to placental transfer increase as well as volume dilution.

Because L-Car plays an important role in fatty acid  $\beta$ -oxidation, it is reasonable to be speculated that plasma L-Car concentration reduction during pregnancy might lead to  $\beta$ -oxidation decrease and plasma lipids rise. However, the hepatic level of  $\beta$ -hydroxybutyrate was significantly higher in GD 18 mice than that in non-pregnant mice (Fig. 7B), which means that the  $\beta$ -oxidation of fatty acids in the liver of GD 18 mice was higher than that of non-pregnant mice. We considered that it might be due to the increased expression of *Acs11*, *Cpt1a*, *Hmgcs2* and *Hmgcl*, and the higher concentration of L-Car in the liver of GD 18 mice (Fig. 7, A, D and E). On the other hand, L-Car level in the heart of GD 18 mice was lower than that of non-pregnant mice, while no difference was found in the muscle (Supplemental Fig. 2).

Nevertheless, Liu et al. (2017) found that fatty acid uptake and oxidation in the heart of late pregnant mice were increased. Taken together, we considered that decreased plasma L-Car levels might not be responsible for elevated plasma TG and TC in pregnancy. Since elevated TG levels throughout pregnancy have been shown to increase the risk of adverse pregnancy outcomes, including gestational diabetes mellitus, preeclampsia and preterm birth (Spracklen et al., 2014; Ryckman et al., 2015; Zheng et al., 2018), the mechanisms of plasma TG and TC rise during pregnancy are already under study in our lab.

It is unknown whether such low L-Car concentrations in pregnant women will induce adverse consequences. Nevertheless, it is possible that a higher L-Car status could have beneficial effects on pregnant women and their fetuses due to the important functions of L-Car. Thus, a strict vegetarian diet should be avoided during pregnancy because vegetables contain much less L-Car than meat and fish (Pochini et al., 2019). It has been reported that L-Car supplementation can prevent the marked decrease of plasma L-Car concentration and the striking increase of plasma free fatty acids in pregnant women (Keller et al., 2009). However, it remains unknown whether supplementation of L-Car will reduce plasma TG and TC in pregnant women, which needs further study.

In conclusion, our results confirmed that maternal plasma L-Car concentration was reduced in pregnancy, which was mainly attributed to placental transfer of L-Car mediated by OCTN2 but not renal excretion increase, and OCTN2 was up-regulated as gestation proceeds in human placenta. Unexpectedly, the reduction of maternal

plasma L-Car level did not induce decrease in hepatic L-Car concentration and fatty acid  $\beta$ -oxidation in mice, thus it was not the main cause of plasma lipid levels rise during pregnancy.



### **Authorship Contributions**

*Participated in research design:* Bai, Sun, Zheng, S. Zeng and Jiang

*Conducted experiments:* Bai, Q. Zeng, Y. Chen, M. Chen and Li

*Performed data analysis:* Bai, Ma, Zhou and Jiang

*Wrote or contributed to the writing of the manuscript:* Bai, Q. Zeng and Jiang

### References:

- Alemu A, Abebe M, Biadgo B, Terefe B and Baynes HW (2018) Biochemical Profiles of Pregnant and Non-pregnant Women Attending at the University of Gondar Hospital, Northwest Ethiopia: A Comparative Cross-sectional Study. *Ethiop J Health Sci* **28**:331-340.
- Amat D, Wang Y and Longo N (2003) Functional domains in the carnitine transporter OCTN2, defective in primary carnitine deficiency. *J Biol Chem* **278**:47776-47784.
- Bai M, Ma Z, Sun D, Zheng C, Weng Y, Yang X, Jiang T and Jiang H (2017) Multiple drug transporters mediate the placental transport of sulpiride. *Arch Toxicol* **91**:3873-3884.
- Cederblad G, Fahraeus L and Lindgren K (1986) Plasma carnitine and renal-carnitine clearance during pregnancy. *Am J Clin Nutr* **44**:379-383.
- Cho SW and Cha YS (2005) Pregnancy increases urinary loss of carnitine and reduces plasma carnitine in Korean women. *Br J Nutr* **93**:685-691.
- Coskun A and Dogan M (2002) Liver L-carnitine biosynthesis in non-pregnant, pregnant and lactating rabbits. *Res Commun Mol Pathol Pharmacol* **111**:211-223.
- Costantine MM (2014) Physiologic and pharmacokinetic changes in pregnancy. *Front Pharmacol* **5**:65.
- D'Argenio G, Petillo O, Margarucci S, Torpedine A, Calarco A, Koverech A, Boccia A, Paolella G and Peluso G (2010) Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis. *J Biol Chem*

**285:27078-27087.**

Enomoto A, Wempe MF, Tsuchida H, Shin HJ, Cha SH, Anzai N, Goto A, Sakamoto A, Niwa T, Kanai Y, Anders MW and Endou H (2002) Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. *J Biol Chem* **277**:36262-36271.

Fernandez OM (1989) Effect of dietary lysine level and protein restriction on the lipids and carnitine levels in the liver of pregnant rats. *Ann Nutr Metab* **33**:162-169.

Foster DW (2004) The role of the carnitine system in human metabolism. *Ann N Y Acad Sci* **1033**:1-16.

Frigeni M, Balakrishnan B, Yin X, Calderon F, Mao R, Pasquali M and Longo N (2017) Functional and molecular studies in primary carnitine deficiency. *Hum Mutat* **38**:1684-1699.

Grube M, Meyer ZSH, Draber K, Prager D, Moritz KU, Linnemann K, Fusch C, Jedlitschky G and Kroemer HK (2005) Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. *Drug Metab Dispos* **33**:31-37.

Hahn P (1981) The development of carnitine synthesis from gamma-butyrobetaine in the rat. *Life Sci* **28**:1057-1060.

Jung C, Ho JT, Torpy DJ, Rogers A, Doogue M, Lewis JG, Czajko RJ and Inder WJ (2011) A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. *J Clin Endocrinol Metab* **96**:1533-1540.

Keller U, van der Wal C, Seliger G, Scheler C, Ropke F and Eder K (2009) Carnitine

status of pregnant women: effect of carnitine supplementation and correlation between iron status and plasma carnitine concentration. *Eur J Clin Nutr* **63**:1098-1105.

La Marca A, Giulini S, Orvieto R, De Leo V and Volpe A (2005) Anti-Mullerian hormone concentrations in maternal serum during pregnancy. *Hum Reprod* **20**:1569-1572.

Lahjouji K, Elimrani I, Wu J, Mitchell GA and Qureshi IA (2002) A heterozygote phenotype is present in the *jvs +/-* mutant mouse livers. *Mol Genet Metab* **76**:76-80.

Lahjouji K, Elimrani I, Lafond J, Leduc L, Qureshi IA and Mitchell GA (2004) L-Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2. *Am J Physiol Cell Physiol* **287**:C263-C269.

Layton J, Powe C, Allard C, Battista MC, Doyon M, Bouchard L, Perron P, Wessel J and Hivert MF (2019) Maternal lipid profile differs by gestational diabetes physiologic subtype. *Metabolism* **91**:39-42.

Li L, Weng Y, Wang W, Bai M, Lei H, Zhou H and Jiang H (2017) Multiple organic cation transporters contribute to the renal transport of sulpiride. *Biopharm Drug Dispos* **38**:526-534.

Lindsay KL, Hellmuth C, Uhl O, Buss C, Wadhwa PD, Koletzko B and Entringer S (2015) Longitudinal Metabolomic Profiling of Amino Acids and Lipids across Healthy Pregnancy. *PLoS One* **10**:e0145794.

Liu LX, Rowe GC, Yang S, Li J, Damilano F, Chan MC, Lu W, Jang C, Wada S,

Morley M, Hesse M, Fleischmann BK, Rabinowitz JD, Das S, Rosenzweig A and Arany Z (2017) PDK4 Inhibits Cardiac Pyruvate Oxidation in Late Pregnancy. *Circ Res* **121**:1370-1378.

Longo N, Frigeni M and Pasquali M (2016) Carnitine transport and fatty acid oxidation. *Biochim Biophys Acta* **1863**:2422-2435.

Luo H, Zhang Y, Guo H, Zhang L, Li X, Ringseis R, Wen G, Hui D, Liang A, Eder K and He D (2014) Transcriptional regulation of the human, porcine and bovine OCTN2 gene by PPARalpha via a conserved PPRE located in intron 1. *BMC Genet* **15**:90.

Luo J, Qu J, Yang R, Ge MX, Mei Y, Zhou BT and Qu Q (2016) Phytochemicals Mediate the Expression and Activity of OCTN2 as Activators of the PPARgamma/RXRalpha Pathway. *Front Pharmacol* **7**:189.

Ma Z, Yang X, Jiang T, Bai M, Zheng C, Zeng S, Sun D and Jiang H (2017) Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. *Drug Metab Dispos* **45**:269-278.

Marzo A, Cardace G, Corbellella C, Pace S, D'Iddio S, Verrotti C, Cavatorta E and Grignaffini A (1994) Plasma concentration, urinary excretion and renal clearance of L-carnitine during pregnancy: a reversible secondary L-carnitine deficiency. *Gynecol Endocrinol* **8**:115-120.

Nakanishi T, Hatanaka T, Huang W, Prasad PD, Leibach FH, Ganapathy ME and Ganapathy V (2001) Na<sup>+</sup>- and Cl<sup>-</sup>-coupled active transport of carnitine by the amino acid transporter ATB(0,+)<sub>1</sub> from mouse colon expressed in HRPE cells and *Xenopus* oocytes. *J Physiol* **532**:297-304.

Pecks U, Rath W, Kleine-Eggebrecht N, Maass N, Voigt F, Goecke T, Mohaupt M and Escher G (2016) Maternal Serum Lipid, Estradiol, and Progesterone Levels in Pregnancy, and the Impact of Placental and Hepatic Pathologies. *Geburtshilfe und Frauenheilkunde* **76**:799-808.

Pochini L, Galluccio M, Scalise M, Console L and Indiveri C (2019) OCTN: A Small Transporter Subfamily with Great Relevance to Human Pathophysiology, Drug Discovery, and Diagnostics. *SLAS Discov* **24**:89-110.

Ramsay RR, Gandour RD and van der Leij FR (2001) Molecular enzymology of carnitine transfer and transport. *Biochim Biophys Acta* **1546**:21-43.

Rebouche CJ, Bosch EP, Chenard CA, Schabold KJ and Nelson SE (1989) Utilization of dietary precursors for carnitine synthesis in human adults. *J Nutr* **119**:1907-1913.

Ringseis R, Hanisch N, Seliger G and Eder K (2010) Low availability of carnitine precursors as a possible reason for the diminished plasma carnitine concentrations in pregnant women. *BMC Pregnancy Childbirth* **10**:17.

Ryckman KK, Spracklen CN, Smith CJ, Robinson JG and Saftlas AF (2015) Maternal lipid levels during pregnancy and gestational diabetes: a systematic review and meta-analysis. *BJOG* **122**:643-651.

Rytting E and Audus KL (2008) Contributions of phosphorylation to regulation of OCTN2 uptake of carnitine are minimal in BeWo cells. *Biochem Pharmacol* **75**:745-751.

Sekine T, Kusuhara H, Utsunomiya-Tate N, Tsuda M, Sugiyama Y, Kanai Y and Endou H (1998) Molecular cloning and characterization of high-affinity carnitine

- transporter from rat intestine. *Biochem Biophys Res Commun* **251**:586-591.
- Shenai JP and Borum PR (1984) Tissue carnitine reserves of newborn infants. *Pediatr Res* **18**:679-682.
- Soldin OP, Guo T, Weiderpass E, Tractenberg RE, Hilakivi-Clarke L and Soldin SJ (2005) Steroid hormone levels in pregnancy and 1 year postpartum using isotope dilution tandem mass spectrometry. *Fertil Steril* **84**:701-710.
- Spracklen CN, Smith CJ, Saftlas AF, Robinson JG and Ryckman KK (2014) Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. *Am J Epidemiol* **180**:346-358.
- Talian GC, Komlosi K, Decsi T, Koletzko B and Melegh B (2007) Determination of carnitine ester patterns during the second half of pregnancy, at delivery, and in neonatal cord blood by tandem mass spectrometry: complex and dynamic involvement of carnitine in the intermediary metabolism. *Pediatr Res* **62**:88-92.
- Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, Shimane M and Tsuji A (1997) Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. *FEBS Lett* **419**:107-111.
- Tamai I, Ohashi R, Nezu JI, Sai Y, Kobayashi D, Oku A, Shimane M and Tsuji A (2000) Molecular and functional characterization of organic cation/carnitine transporter family in mice. *J Biol Chem* **275**:40064-40072.
- Vaz FM and Wanders RJ (2002) Carnitine biosynthesis in mammals. *Biochem J* **361**:417-429.
- Wang C, Kong L, Yang Y, Wei Y, Zhu W, Su R, Lin L and Yang H (2018)

Recommended reference values for serum lipids during early and middle pregnancy:

a retrospective study from China. *Lipids Health Dis* **17**:246.

Wang W, Bai M, Jiang T, Li C, Li P, Zhou H, Wang Z, Li L and Jiang H (2019)

Clozapine-induced reduction of l-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice. *Toxicol Appl Pharmacol* **363**:47-56.

Winter SC Linn LS and Helton E (1995) Plasma carnitine concentrations in pregnancy, cord blood, and neonates and children. *Clin Chim Acta* **243**:87-93.

Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH and Ganapathy V (2000) Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. *Biochim Biophys Acta* **1466**:315-327.

Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y and Tsuji A (1999) Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. *J Pharmacol Exp Ther* **289**:768-773.

Zhang Z, Farooq M, Prasad B, Grepper S and Unadkat JD (2015) Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes. *Drug Metab Dispos* **43**:836-842.

Zheng W, Huang W, Zhang L, Tian Z, Wang T, Zhang T, Zhang Z, Zhang W and Li G (2018) Changes in Serum Lipid Levels During Pregnancy and Association With Neonatal Outcomes: A Large Cohort Study. *Reprod Sci* **25**:1406-1412.



### **Footnotes**

This work was supported by the National Natural Science Foundation of China [Grant No.81573492, 81773804]; and Zhejiang Province Natural Science Foundation of China [Grant No. LZ17H300001].

## Legends for Figures

**Fig.1** The concentration of L-Car in plasma of non-pregnant and pregnant mice at GD 18. Data are expressed as mean  $\pm$  SEM, n = 10. Compared with the non-pregnant group,  $**P < 0.01$ .

**Fig. 2** (A) The concentration of L-Car in maternal and fetal plasma of mice at GD 18. Data are expressed as mean  $\pm$  SEM, n = 10. (B) The mRNA level of carnitine transporters in mouse placenta at GD 15 and 18. Data are expressed as mean  $\pm$  SEM, n = 8. Compared with the GD 15 placenta,  $***P < 0.001$ . (C) The mRNA level of carnitine transporters and protein level of OCTN2 (D) in the first trimester placenta and term human placenta. Data are expressed as mean  $\pm$  SEM (n = 32 for first trimester placenta and n = 23 for term placenta). Compared with the first trimester placenta,  $***P < 0.001$ . ND, not detected. (E) Immunohistochemical detection of OCTN2 in the human term placenta. Representative images shown were captured at 200  $\times$  (left panel) and 400  $\times$  (right panel) magnification.

**Fig. 3** (A) L-Car excretion in mouse urine. On gestational day (GD) 16 – 18 and lactation day (LD) 8 – 10, urine samples within 24 h from pregnant or postpartum mice were collected. On another successive 3 days (day 1 – day 3), urine samples within 24 h from non-pregnant mice were collected. Data are expressed as mean  $\pm$  SEM, n = 5. The concentration of L-Car (B) and mRNA levels of carnitine transporters (C) in the kidney of non-pregnant and pregnant mice at GD 18. Data are expressed as mean  $\pm$  SEM, n = 10. Compared with the non-pregnant group,  $***P < 0.001$ .

**Fig. 4** The effect of E2 (A), P4 (B), 10  $\mu$ M CORT and cortisol (C) on the mRNA expression of OCTN2 in HK-2 cells, and the concentration of L-Car in HK-2 cells in response to P4 (D) treatment. Cells were incubated with or without designated concentrations of hormones for 24 h. Data are expressed as mean  $\pm$  SEM from two independent experiments conducted in triplicate. Compared with the control, \* $P$  < 0.05, \*\* $P$  < 0.01, \*\*\* $P$  < 0.001.

**Fig. 5** The mRNA expression of PPAR $\alpha$  (A) and PPAR $\gamma$  (B) in HK-2 cells in response to P4 treatment, and the effect of WY14643 (100  $\mu$ M) on 20  $\mu$ M P4-induced down-regulation of OCTN2 (C) and PPAR $\alpha$  (D). Data are expressed as mean  $\pm$  SEM from two independent experiments conducted in triplicate. Compared with the control, \* $P$  < 0.05, \*\* $P$  < 0.01, \*\*\* $P$  < 0.001. Compared with the 20  $\mu$ M P4 group, ### $P$  < 0.001. (E) The mRNA level of Ppar $\alpha$  in the kidney of non-pregnant and pregnant mice at GD 18. Data are expressed as mean  $\pm$  SEM,  $n$  = 10. Compared with the non-pregnant group, \* $P$  < 0.05.

**Fig. 6** The effect of E2 (A), P4 (B), 100  $\mu$ M CORT and cortisol (C) on the d<sub>3</sub>-L-Car accumulation in MDCK-hOCTN2 cells. Cells were incubated with 3  $\mu$ M d<sub>3</sub>-L-Car in the absence or presence of designated concentrations of hormones for 3 min. (D) The effect of P4 on the d<sub>3</sub>-L-Car accumulation in HK-2 cells. Cells were incubated with 10  $\mu$ M d<sub>3</sub>-L-Car in the absence or presence of L-Car (positive control) or P4 for 10 min. Uptake is expressed as the percentage of d<sub>3</sub>-L-Car accumulation without inhibitors. Data are expressed as mean  $\pm$  SEM from two independent experiments conducted in triplicate. Compared with the control, \*\*\* $P$  < 0.001.

**Fig.7** The concentration of L-Car in the liver (A); the concentration of  $\beta$ -hydroxybutyrate in the liver (B) and serum (C); the mRNA levels of key enzymes involved in fatty acid  $\beta$ -oxidation (D) and  $\beta$ -hydroxybutyrate synthesis (E) in the liver of non-pregnant and pregnant mice at GD 18. Data are expressed as mean  $\pm$  SEM, n = 10. Compared with the non-pregnant group, \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .










Figure 1



**Figure 2**




**Figure 3**



**Figure 4**





**Figure 5**








Figure 6



**Figure 7**

*Drug Metabolism and Disposition*

Supplementary Information

**Maternal plasma L-carnitine reduction during pregnancy is mainly attributed to OCTN2 mediated placental uptake and does not result in maternal hepatic fatty acid  $\beta$ -oxidation decline**


Mengru Bai, Qingquan Zeng, Yingchun Chen, Mingyang Chen, Ping Li, Zhiyuan Ma,

Dongli Sun, Hui Zhou, Caihong Zheng, Su Zeng, and Huidi Jiang


Laboratory of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China (M.B., Y.C., M.C., P.L., Z.M., H.Z., S.Z., H.J.)

Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China (Q.Z., D.S., C.Z.)

## Supplementary figures and tables



**Fig. S1** (A) The accumulation of ergothioneine and d<sub>3</sub>-L-Car in MDCK-hOCTN1 and mock cells. (B) The concentration of L-Car in MDCK-hOCTN1, MDCK-hOCTN2 and mock cells. Data are expressed as mean  $\pm$  SEM from two independent experiments conducted in triplicate. Compared with the accumulation in mock cells, \*\*\* $P < 0.001$ .



**Fig. S2** The concentrations of L-Car in the heart and muscle of non-pregnant and pregnant mice at gestation day (GD) 18. Data are expressed as mean  $\pm$  SEM,  $n = 10$ . Compared with the non-pregnant group, \*\* $P < 0.01$ .

**Supplemental Table 1**

Primers used in quantitative real-time polymerase chain reaction (qRT-PCR)

| Gene               | accession number | Direction | Sequence(5→3)               | Product Length (bp) |
|--------------------|------------------|-----------|-----------------------------|---------------------|
| Ct1                | NM_001039371.2   | Forward   | GGCCTTTGTCTTGCTAAATGA       | 70                  |
|                    |                  | Reverse   | GAGACCACCAATCGATCCTG        |                     |
| Ct2                | NM_027572.1      | Forward   | GTCCTCGCTCACCTGTATGC        | 65                  |
|                    |                  | Reverse   | CCATCCTTTTCGCAGTCTTG        |                     |
| Octn2              | NM_011396.3      | Forward   | CACGATGGCTCATCTCTCAA        | 73                  |
|                    |                  | Reverse   | CCATTGATTTTGGCAGCTTT        |                     |
| Atb <sup>0,+</sup> | NM_020049.4      | Forward   | GAAGTTTTTTCGGCCAGGAC        | 78                  |
|                    |                  | Reverse   | ATCCATTCCACTTGACCTCTG       |                     |
| Ppara              | NM_011144.6      | Forward   | CACGCATGTGAAGGCTGTAA        | 78                  |
|                    |                  | Reverse   | GCTCCGATCACACTTGTCG         |                     |
| Acs11              | NM_007981.4      | Forward   | TGCCAGAGCTGATTGACATTC       | 101                 |
|                    |                  | Reverse   | GGCATAACCAGAAGGTGGTGAG      |                     |
| Cpt1a              | NM_013495.2      | Forward   | GACTCCGCTCGCTCATTC          | 62                  |
|                    |                  | Reverse   | TCTGCCATCTTGAGTGGTGA        |                     |
| Acadv1             | NM_017366.3      | Forward   | GGTGGTTTGGGCCTCTCTA         | 82                  |
|                    |                  | Reverse   | GGGTAACGCTAACACCAAGG        |                     |
| Acad1              | NM_007381.4      | Forward   | GCTTATGAATGTGTGCAACTCC      | 81                  |
|                    |                  | Reverse   | CCGAGCATCCACGTAAGC          |                     |
| Acadm              | NM_007382.5      | Forward   | AGTACCCTGTGGAGAAGCTGAT      | 100                 |
|                    |                  | Reverse   | TCAATGTGCTCACGAGCTATG       |                     |
| Acads              | NM_007383.3      | Forward   | AGGTCCCTGGAGGTCTGTGC        | 86                  |
|                    |                  | Reverse   | CAGTCCCGAACACCGAGA          |                     |
| Hadh               | NM_008212.4      | Forward   | TGGATACTACAAAGTTCATCTTGGA   | 75                  |
|                    |                  | Reverse   | AAGGACTGGGCTGAAATAAGG       |                     |
| Hadha              | NM_178878.2      | Forward   | TTCTTAAAGACACCACAGTGACG     | 80                  |
|                    |                  | Reverse   | CTTCTTCACTTTGTCGTTTCAGC     |                     |
| Hadhb              | NM_145558.2      | Forward   | TGAAAACAAGCAATGTGGCTA       | 95                  |
|                    |                  | Reverse   | TGAAGAGATAACAAGCCATGGTG     |                     |
| Hmgcs2             | NM_008256.4      | Forward   | ATACCACCAACGCCTGTTATGG      | 111                 |
|                    |                  | Reverse   | CAATGTCACCACAGACCACCAG      |                     |
| Hmgcl              | NM_008254.3      | Forward   | ACTACCCAGTCCTGACTCCAA       | 123                 |
|                    |                  | Reverse   | TAGAGCAGTTCGCGTTCTTCC       |                     |
| Bdh1               | NM_175177.4      | Forward   | GCTTCCTTGTATTTGCTGGC        | 130                 |
|                    |                  | Reverse   | TTCTCCACCTCTTCACTGTTG       |                     |
| Gapdh              | NM_008084.2      | Forward   | TGTGTCCGTCGTGGATCTGA        | 150                 |
|                    |                  | Reverse   | TTGCTGTTGAAGTCGCAGGAG       |                     |
| CT1                | NM_018420.2      | Forward   | TTGTCTTATTGTAATGTTTCTTCCAGA | 112                 |

|                   |             |         |                           |     |
|-------------------|-------------|---------|---------------------------|-----|
|                   |             | Reverse | GTAAAGGCAGCACTGATGGT      |     |
| CT2               | NM_033125.2 | Forward | GCTGAGCTGTATCCAACCATT     | 104 |
|                   |             | Reverse | CTGCTGAGGTCCACAGAGAAC     |     |
| OCTN2             | NM_003060.3 | Forward | GCAGCATCCTGTCTCCCTAC      | 91  |
|                   |             | Reverse | GCTGTCAGGATGGTCAGACTT     |     |
| ATB <sup>0+</sup> | NM_007231.5 | Forward | TGAAATGCCCGAGTTTCTTC      | 61  |
|                   |             | Reverse | TTCTCTGATGAAGCCGACACT     |     |
| PPAR $\alpha$     | NM_005036.5 | Forward | GCTTTGGCTTTACGGAATACCA    | 77  |
|                   |             | Reverse | TGAAAGCGTGTCCGTGATGA      |     |
| PPAR $\gamma$     | NM_005037.5 | Forward | ATCTCTCCGTAATGGAAGACCACTC | 488 |
|                   |             | Reverse | CCCAAACCTGATGGCATTATGAGAC |     |
| GAPDH             | NM_002046.7 | Forward | GCACCGTCAAGGCTGAGAAC      | 138 |
|                   |             | Reverse | TGGTGAAGACGCCAGTGGA       |     |

---